Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD133 in Relapsed or Refractory MSLN-Positive Solid Tumors
NCT05141253Phase 1Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jan 2022
- Primary completion
- Nov 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD133 in solid tumor, sponsored by Tongji Hospital. Primary endpoints: Dose-limiting toxicity at 5 years and Adverse events and serious adverse events at 5 years. Started Jan 2022; status: recruiting.
02
Drugs
RD133
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05141253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05141253.